Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Adaptive, Phase IIb/III, Double-Blind, Randomized, Placebo-Controlled, Multi-Center Study of the Safety and Efficacy OF NaBen® , A D-Amino Acid Oxidase Inhibitor, as an Add-on Treatment for Schizophrenia in Adolescents

NCT01908192 is registered in ClinicalTrials.gov with SyneuRx International (Taiwan) Corp as lead sponsor.

NCT NCT01908192
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01908192 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Adaptive, Phase IIb/III, Double-Blind, Randomized, Placebo-Controlled, Multi-Center Study of the Safety and Efficacy OF NaBen® , A D-Amino Acid Oxidase Inhibitor, as an Add-on Treatment for Schizophrenia in Adolescents
Lead sponsor
SyneuRx International (Taiwan) Corp
Phase
Phase 2/3
Overall status
Terminated
Start date
June 30, 2014
Completion date
October 26, 2023
Enrollment
60 (actual)
Sites
23

Conditions

As the registry lists them; a condition with its own page is linked.

schizophrenia